News

Christian Lienhardt Discusses the Newly Launched TB-PACTS Database

Christian Lienhardt, from WHO, discusses the launch of TB-PACTS, the new data-sharing platform for TB clinical trials. This marks the beginning of an exciting new tool in the fight against TB. Announced on April 18th, TB-PACTS combines clinical trial data from Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, and St. George’s, University of London. Hosted on the C-PATH website, it strives to standardize all Phase III tuberculosis clinical trial data. According to the website, “researchers can access and analyze data in aggregate, or filter and view individual patient-level data from the REMoxTB, RIFAQUIN and OFLUTUB clinical trials”.

TB-PACTS, which stands for TB-Platform for Aggregation of Clinical TB Studies, is accessible to researchers after registering an online application. The website informs users it may take up to 4 weeks for the application to be processed. Once registered users are able and encouraged to contribute data as well. The site assures users that they retain ownership of their data and that the platform is secure.

As Dr. Lienhardt discusses, having a larger database improves and refines the ability to analyze the data. It provides an increased sample size, an opportunity to perform analysis of specific populations, and an increased likelihood of finding commonalities that were not picked up in the single trials.

Related Links

TB-PACTS Website

Christian Lienhardt Discusses TB-PACTS

TB-PACTS Press Release

More News
22 Mar 2017
March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive...
10 Mar 2017
WGND Co-chair, Barbara Laughon, and Sequella Inc. CEO, Carol Nacy, co-authored a correspondence to Nature Reviews regarding the October 2016 Article, “Tuberculosis”. “In their recent Primer article (Tuberculosis. Nat. Rev. Dis. Primers 2, 16076 (2016))1, Madhukar Pai and colleagues give an...
1 Mar 2017
28 FEBRUARY 2017 | GENEVA - WHO reaffirms the critical need for research and development (R&D) of new antibiotics to tackle the threat of drug-resistant tuberculosis (TB). "Addressing drug-resistant TB research is a top priority for WHO and for the world," said Dr Margaret Chan, WHO Director-...